[Advances in basic and clinical research of flumatinib]

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myelogenous leukemia (CML) is a stem cell malignancy.
• Imatinib, a first-generation tyrosine kinase inhibitor (TKI), transformed CML treatment.
• Novel TKIs are needed to improve CML therapy.

Purpose of the Study:

• To evaluate flumatinib, a novel oral TKI developed in China, as a preferred treatment for CML.
• To compare the efficacy and potency of flumatinib against imatinib in CML.
• To assess flumatinib's activity in CML with mutations, Ph(+) acute lymphoblastic leukemia, and solid tumors.

Main Methods:

• In vitro studies on CML cell lines.
• Clinical trials and real-world studies in CML patients.
• Evaluation of efficacy against specific mutations and other malignancies.

Main Results:

• Flumatinib demonstrated a stronger inhibitory effect on CML cell lines than imatinib.
• Clinical and real-world data indicate superior efficacy of flumatinib over imatinib in CML.
• Flumatinib showed enhanced potency against CML with mutations, Ph(+) acute lymphoblastic leukemia, and some solid tumors.
• Adverse events associated with flumatinib were manageable and tolerable.

Conclusions:

• Flumatinib is a highly effective and well-tolerated oral TKI for CML treatment.
• Flumatinib offers a promising therapeutic option for CML, including cases with specific mutations.
• The drug's efficacy extends to other hematological and solid tumors, warranting further investigation.